DJIA 17,804.80 26.65 0.15%
NASDAQ 4,765.38 16.98 0.36%
S&P 500 2,070.65 9.42 0.46%
market minute promo

Pfizer (NYSE: PFE)

31.94 -0.03 (-0.09%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PFE $31.94 -0.09%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $31.91
Previous Close $31.97
Daily Range $31.61 - $32.09
52-Week Range $27.51 - $33.12
Market Cap $201.2B
P/E Ratio 19.73
Dividend (Yield) $1.12 (3.5%)
Ex-Dividend Date
Dividend Pay Date
02/04/15
03/03/15
Volume 44,940,797
Average Daily Volume 23,936,502
Current FY EPS $2.26

Sector

Healthcare

Industry

Drugs

Pfizer (PFE) Description

A research-based pharmaceutical company, Pfizer discovers, develops, manufactures, and markets prescription medicines such as Lipitor, Celebrex, and Viagra. Website: http://www.pfizer.com/

News & Commentary

The Most Disappointing Clinical Failures in 2014

Three Motley Fool contributors tell us what they think were the biggest drug trial failures this year.

Update: In A Surprise Twist, AstraZeneca Wins Accelerated FDA Approval For Lynparza

5 Crazy Habits You Might Adopt With Low-Cost Genome Sequencing

A full human genome can now be sequenced for $1,000. That's still a little pricey for mass adoption, but Illumina and Pacific Biosciences could bring the cost down even further -- opening up the genomics floodgates.

Why Is George Soros Buying This Beaten Down Biotech Stock?

Soros Fund Management opened a position in the struggling biotech Aegerion Pharmaceuticals in the third quarter, even while the drugmaker's revenue estimates continued to plummet. Should retail investors follow his lead into this beaten down biotech?

Update: Ligand Wins EU Approval For Duavive

Exciting News: A Game-Changing Shingles Vaccine Could Be On Its Way

GlaxoSmithKline plc has reported impressive late stage trial results for its shingles vaccine.

United Therapeutics Lung Drug Keeps Going And Going

3 Pharma Giants Growing Significantly Faster Than Pfizer, Inc.

Pfizer is a staple in most retirement and income portfolios, but investors can find stronger growth prospects in each of these three big pharmaceutical stocks.

Update: AstraZeneca Wins EU Approval For Lynparza

Pfizer's Duchenne Muscular Dystrophy Drug in Phase II - Analyst Blog

Pfizer's Duchenne Muscular Dystrophy Drug in Phase II - Analyst Blog

See More PFE News...

PFE's Top Competitors

PFE $31.94 (-0.09%)
Current stock: PFE
JNJ $105.55 (-1.18%)
Current stock: JNJ
ROG $79.15 (9.93%)
Current stock: ROG
GSK $43.35 (0.14%)
Current stock: GSK